Flow References






CART Tracking Celluler Kinetics and Biodistribution of CAR T-Cells: Clinical Trial Considerations and Case Studies   WRIB 2023
CART Why implementation of patient centric biomarker solutions for cell & gene therapies is vital?   TriCon 2023
ALL Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy and Safety by Baseline CD22  Clinical Cancer Research  
heme Development of DeepCytoFlow: A novel deep learning pipeline enabling automated gating of flow cytometry data   AACR
Melanoma Neoadjuvant Pembrolizumab and High Dose Interferon Alfa-2b in Resectable Regionally Advanced Melanoma Clinical Cancer Research  
Heme 2020 White Paper on Recent Issues in Bioanalysis:
BAV Guidance, CLSI H62, Biotherapeutics Stability, Parallelism Testing, CyTOF and Regulatory Feedbacks
Melanoma Multimarker scores of Th1 and Th2 immune cellular profiles in baseline peripheral blood mononuclear cells predict response and immune related toxicity with CTLA4 blockade and IFNα in Melanoma Translational Research  
heme Flow Cytometry in CAR-T Therapies: Challenges and Solutions   AAPS-OSD (Open Scientific Discussion) forum 
Heme Best Practices for the development, analytical validation and clinical implementation of flow cytometric methods for chimeric antigen receptor T cell (CAR T) analyses  Clinical Cytometry   
AML (heme) Best Practices for Validation of Measurable Residual Disease Assessments by Multiparameter Flow Cytometry in Emerging Clinical Trials of Acute Myeloid Leukemia   ASH
Pan tumor A multiparameter flow cytometry assay to monitor natural killer cell proliferation and activation in immuno-oncology clinical trials   SITC
MF (heme) A multiparameter flow cytometry assay to monitor megakaryocytes and leukemic cells in clinical trials of myelofibrosis patients   ICCS
Heme Monitoring CAR-T Cell Kinetics in Clinical Trials by Multiparameter Flow Cytometry: Benefits and Challenges Clinical Cytometry   
Melanoma Predictive value of circulating B cells and T cell subsets in melanoma patients treated with neoadjuvant ipilimumab and interferon α   ASCO
Heme High Dimensional Flow Cytometry in Immuno-Oncology   WRIB
Heme CAR-T monitoring by flow cytometry: Assuring Quality While Acknowledging Limitations   WRIB
Pan Tumor High Dimensional Flow Cytometery in IO   PMWC
Heme 2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (SECTION 3 – Flow Cytometry Validation in Drug Discovery & Development & CLSI H62). Bioanalysis   
Heme 2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (SECTION 5 – In vivo & Ex vivo Gene Therapy & Vaccine Bioanalytical Challenges). Bioanalysis   
ALL Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial Leukemia Research  
ALL Efficacy and Safety Outcomes in the Phase 3 INO-VATE Trial by Baseline CD22-Positivity Assessed by Local Laboratories   ASH
Melanoma Immunomodulatory effects of interleukin 2 in the circulation of melanoma patients and the added impact of VEGF inhibition with ziv-aflibercept    SITC
Solid Tumor Development of a slide-based multiplex immunofluorescent assay for detection of Helios degradation and DKY709 PD analysis   Novartis Onc Retreat
Pan Tumor Efficacy and Safety Biomarkers of Cancer lmmunotherapies Identified by Novel Digital Pathology and Flow Cytometry Approaches   Biomarkers and Precision Medicine Conference
Melanoma Application of High Complexity Flow Cytometry for Monitoring activated T-cells, T and B Regulatory Subsets in Combination Immunotherapy Trials, Melanoma Case Study   AACR
Heme On-going developments in CAR-T Bioanalytical Strategies & Challenges by Flow Cytometry    WRIB
Heme Molecular and flow cytometry analytical approaches and challenges for assessing cellular kinetics, efficacy and product characterization for gene therapy products   WRIB
ALL Comparison of CD22 Expression Levels Between Baseline and End of Treatment Among Patients treated with Inotuzumab Ozogamicin in Two Clinical Trials.    ASH
Melanoma Multimarker scores of Th1 and Th2 cellular profiles in baseline PBMCs predict response and toxicity with Ipilimumab and IFNα2b neoadjuvant therapy in Melanoma   SITC
ALL Genetic alterations in CD19 lead to CD19 negative relapse to CAR19 therapy in children and young adults with relapsed/refractory acute lymphoblastic leukemia.  Nature Medicine  
Melanoma High Complexity All-in-One Flow Cytometry Assay for the Measurement of T-cell Activation, Checkpoint Inhibitor Expression and Proliferation of T-cells in Periphery as a Biomarker for Novel Immuno-oncology Clinical Trials   ICCS
Melanoma Assessment of Monocytes, MDSCs and Myeloid Cell Populations in Immuno-Oncology Clinical Trials by a Standardized High Complexity Flow Cytometry Approach   ICCS
ALL CAR-T Characterization by Flow Cytometry: Hurdles and Successes. Bioanalytical Conference; Madison, WI; July 2018   Bioanalytical Conference
ALL Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Global Phase 3 INOVATE Trial: Efficacy and Safety by Baseline CD22 Expression Level   ASH
ALL Flow Cytometry Approaches for Characterizing Functional Persistence   AAPS
multi Biomarker Sample Stability: Why do we Care?   AAPS
Multiple Myeloma Analytical validation and clinical verification of phosphoprotein biomarker modulation using a novel preservation system-based flow cytometry assay in multiple myeloma clinical trials.    AACR
Hematomalignancy High complexity flow cytometry panels to monitor target expression, T-cell activation and suppression by novel immunotherapies in hematomalignancy clinical trials.    AACR
  The Journey Towards Standardization for Validation of Fluorescent Cell-Based Assays.